triazoles has been researched along with bay 85-3934 in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (40.00) | 24.3611 |
| 2020's | 18 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ellinghaus, P; Flamme, I; Jeske, M; Keldenich, J; Oehme, F; Thuss, U | 1 |
| Buisson, C; Dib, J; Molina, A; Mongongu, C; Schänzer, W; Thevis, M; Thuss, U | 1 |
| Block, GA; Fishbane, S; Locatelli, F; Macdougall, IC | 1 |
| Gupta, N; Wish, JB | 1 |
| Dong, W; Liang, J; Qi, J; Yu, P; Zhang, T; Zhu, C | 1 |
| Akbaba, M; Beck, H; Ergüden, JK; Flamme, I; Hartung, IV; Jeske, M; Karig, G; Keldenich, J; Militzer, HC; Oehme, F; Stoll, F; Thede, K; Thuss, U | 1 |
| Arens, ER; Böttcher, M; Kaiser, A; Kubitza, D; Lentini, S; Thuss, U; van der Mey, D; Wensing, G | 1 |
| Audran, M; Domergue, V; Marchand, A; Roulland, I; Schröder, K; Semence, F | 1 |
| Akizawa, T; Bernhardt, T; Berns, JS; Iekushi, K; Krueger, T; Macdougall, IC; Staedtler, G; Taguchi, M | 1 |
| Akizawa, T; Iekushi, K; Matsuda, Y; Taguchi, M; Yamada, T; Yamamoto, H | 2 |
| Akizawa, T; Bernhardt, T; Berns, JS; Iekushi, K; Macdougall, IC; Taguchi, M; Yamamoto, H | 1 |
| Kaiser, A; Kapsa, S; Lentini, S; Matsuno, K; van der Mey, D | 1 |
| Barwacz, S; Bogacz, T; Dulak, J; Józkowicz, A; Kachamakova-Trojanowska, N; Podkalicka, P; Łoboda, A | 1 |
| Gerisch, M; Kaiser, A; Kern, A; Lentini, S; Matsuno, K; Thuss, U; van der Mey, D | 1 |
| De Wilde, L; Deventer, K; Roels, K; Van Eenoo, P | 1 |
| Kittikulsuth, W; Li, L; Morisawa, N; Nakano, D; Nishiyama, A; Ohsaki, H; Suzuki, N; Yamamoto, M; Zhang, A | 1 |
| Gerisch, M; Jungmann, NA; Kaiser, A; Lentini, S; Radtke, M; Schulz, S; van der Mey, D; Yoshikawa, K | 1 |
| Akizawa, T; Hayasaki, T; Hayashi, Y; Matsuda, Y; Nobori, K; Yamamoto, H | 3 |
| Agoro, R; Allen, MR; Atkins, GJ; Broxmeyer, HE; Capitano, ML; Clinkenbeard, EL; Ni, P; Noonan, ML; Prideaux, M; Sacks, SA; Swallow, EA; Thompson, WR; Wheeler, JA; White, KE | 1 |
| Chowdhury, R; Figg, WD; Holt-Martyn, JP; Krajnc, A; McDonough, MA; Nakashima, Y; Schofield, CJ; Zhang, Z | 1 |
| Barrs, RW; Coyle, RC; Ladd, EP; Mei, Y; Menick, DR; Richards, DJ | 1 |
| Kitada, K; Kittikulsuth, W; Konishi, Y; Morikawa, T; Morisawa, N; Nakano, D; Nishiyama, A; Rahman, A; Zhang, A | 1 |
| Jensen, BL | 1 |
| Grieshober, M; Hauck, S; Mayer, D; Stenger, S; Zenk, SF | 1 |
| Akizawa, T; Hayasaki, T; Hayashi, Y; Matsuda, Y; Nobori, K; Taki, K; Yamamoto, H | 1 |
| Carr, CA; Castro-Guarda, M; Dennis, KMJH; Heather, LC; Massourides, E; Montes Aparicio, CN; Purnama, U; Sousa Fialho, MDL; Tyler, DJ | 1 |
| Hartner, A; Schley, G | 1 |
2 review(s) available for triazoles and bay 85-3934
| Article | Year |
|---|---|
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.
Topics: Anemia; Animals; Barbiturates; Blood Pressure; Disease Models, Animal; Drug Design; Drug Interactions; Glycine; Hepcidins; Humans; Hypoxia-Inducible Factor 1; Inflammation; Isoquinolines; Kidney Failure, Chronic; Picolinic Acids; Protein Domains; Pyrazoles; Triazoles | 2017 |
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Topics: Anemia; Barbiturates; Clinical Trials as Topic; Enzyme Inhibitors; Erythropoietin; Glycine; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Isoquinolines; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2017 |
10 trial(s) available for triazoles and bay 85-3934
| Article | Year |
|---|---|
First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Topics: Administration, Oral; Adult; Anemia; Area Under Curve; Erythropoietin; Half-Life; Healthy Volunteers; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Prolyl-Hydroxylase Inhibitors; Proof of Concept Study; Pyrazoles; Renal Insufficiency, Chronic; Single-Blind Method; Triazoles; Young Adult | 2018 |
Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Darbepoetin alfa; Drug Administration Schedule; Epoetin Alfa; Female; Hematinics; Hemoglobins; Humans; Long-Term Care; Male; Middle Aged; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles | 2019 |
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
Topics: Adult; Anemia; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hematinics; Humans; Male; Practice Guidelines as Topic; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles | 2019 |
Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
Topics: Anemia; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematinics; Humans; Japan; Male; Middle Aged; Prospective Studies; Pyrazoles; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2019 |
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Basic Helix-Loop-Helix Transcription Factors; Double-Blind Method; Female; Hematinics; Hemoglobins; Hepcidins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Iron; Male; Middle Aged; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2019 |
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Topics: Administration, Oral; Adult; Anemia; Area Under Curve; Calcium; Cross-Over Studies; Dietary Supplements; Drug Administration Schedule; Drug Interactions; Erythropoietin; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Iron; Male; Middle Aged; Pyrazoles; Time Factors; Triazoles; Young Adult | 2020 |
Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study.
Topics: Aged; Aged, 80 and over; Anemia; Female; Humans; Japan; Male; Middle Aged; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2021 |
Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study.
Topics: Anemia; Erythropoietin; Hematinics; Hemoglobins; Humans; Japan; Peritoneal Dialysis; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2022 |
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Topics: Aged; Aged, 80 and over; Anemia; Female; Hematinics; Humans; Male; Middle Aged; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2021 |
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Topics: Aged; Aged, 80 and over; Anemia; Female; Humans; Male; Middle Aged; Pyrazoles; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2021 |
18 other study(ies) available for triazoles and bay 85-3934
| Article | Year |
|---|---|
Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
Topics: Anemia; Animals; Erythropoietin; Female; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Macaca fascicularis; Male; Pyrazoles; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Triazoles; Up-Regulation | 2014 |
Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.
Topics: Doping in Sports; Glucuronides; Humans; Hypoxia-Inducible Factor 1; Limit of Detection; Pyrazoles; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection; Triazoles | 2017 |
Adrenomedullin serves a role in the humoral pathway of delayed remote ischemic preconditioning via a hypoxia-inducible factor-1α-associated mechanism.
Topics: Adrenomedullin; Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indazoles; Ischemic Preconditioning; Kidney; Male; Malondialdehyde; Pyrazoles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Superoxide Dismutase; Triazoles; Up-Regulation | 2018 |
Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
Topics: Anemia; Animals; Binding Sites; Cell Line, Tumor; Drug Discovery; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Kidney Diseases; Mice; Molecular Structure; Protein Binding; Protein Conformation; Pyrazoles; Structure-Activity Relationship; Triazoles | 2018 |
Detection of Hypoxia-Regulated MicroRNAs in Blood as Potential Biomarkers of HIF Stabilizer Molidustat.
Topics: Animals; Biomarkers; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; MicroRNAs; Protein Stability; Pyrazoles; Rats; Rats, Wistar; Triazoles | 2019 |
HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred NOD; Mice, SCID; Protein Stability; Pyrazoles; Random Allocation; Triazoles; Xenograft Model Antitumor Assays | 2020 |
Absorption, distribution, metabolism and excretion of molidustat in healthy participants.
Topics: Administration, Oral; Adult; Biological Availability; Drug Evaluation, Preclinical; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Pyrazoles; Tissue Distribution; Triazoles | 2020 |
Automated sample preparation for the detection and confirmation of hypoxia-inducible factor stabilizers in urine.
Topics: Chromatography, Liquid; Doping in Sports; Glycine; Humans; Hypoxia-Inducible Factor 1; Isoquinolines; Limit of Detection; Linear Models; Pyrazoles; Reproducibility of Results; Solid Phase Extraction; Substance Abuse Detection; Tandem Mass Spectrometry; Triazoles | 2021 |
Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
Topics: Acute Kidney Injury; Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hypoxia-Inducible Factor 1; Male; Mice, Inbred C57BL; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Triazoles | 2020 |
Drug-drug interaction of atazanavir on UGT1A1-mediated glucuronidation of molidustat in human.
Topics: Adult; Atazanavir Sulfate; Drug Interactions; Erythropoietin; Glucuronides; Glucuronosyltransferase; Humans; Male; Middle Aged; Pyrazoles; Triazoles; Young Adult | 2021 |
The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
Topics: Anemia; Animals; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Mice; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2021 |
Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat.
Topics: Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Prolyl Hydroxylases; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Structure-Activity Relationship; Triazoles | 2021 |
Targeting HIF-α for robust prevascularization of human cardiac organoids.
Topics: Coculture Techniques; Fibroblasts; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Myocytes, Cardiac; Neovascularization, Physiologic; Organoids; Pyrazoles; Triazoles | 2021 |
Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats.
Topics: Animals; Blood Pressure; Disease Models, Animal; Hypertension; Male; Nephrectomy; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Rats, Wistar; Renal Insufficiency, Chronic; Sodium; Triazoles | 2021 |
Get use to the -dustats: Roxadustat and molidustat, members of the hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor drug class promote kidney function, perfusion and oxygenation in rats through nitric oxide.
Topics: Animals; Glycine; Hypoxia; Isoquinolines; Kidney; Nitric Oxide; Perfusion; Pharmaceutical Preparations; Prolyl Hydroxylases; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Rats; Triazoles | 2021 |
Stabilization of Hypoxia-Inducible Factor Promotes Antimicrobial Activity of Human Macrophages Against
Topics: Basic Helix-Loop-Helix Transcription Factors; Cytokines; Host-Pathogen Interactions; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Macrophages; Models, Biological; Mycobacterium tuberculosis; Protein Stability; Pyrazoles; Receptors, Calcitriol; Triazoles; Tuberculosis | 2021 |
Activation of HIF1α Rescues the Hypoxic Response and Reverses Metabolic Dysfunction in the Diabetic Heart.
Topics: Adaptation, Physiological; Anemia, Sickle Cell; Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Energy Metabolism; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin Resistance; Myocytes, Cardiac; Oxygen; Pluripotent Stem Cells; Pyrazoles; Rats; Triazoles | 2021 |
The prolyl hydroxylase inhibitor molidustat fails to restore erythropoietin production in the fibrotic kidney.
Topics: Erythropoietin; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Kidney; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2022 |